Xeris Biopharma(US:XERS)2020-11-02 18:43Recorlev (levoketoconazole) for Cushing's Syndrome - NDA submission for Recorlev is anticipated in Q1 2021[6], with a potential U S launch in Q1 2022 if approved[71] - Recorlev's addressable market for Cushing's syndrome is estimated to exceed $2 billion annually[6] - Phase 3 SONICS study showed 30% of patients achieved mUFC normalization without a dose increase[34] - Phase 3 LOGICS study demonstrated 54 5% more patients lost response on placebo than on levoketoconazole (p-value: 0 0002)[56] - U S market assessment indicates Recorlev could achieve peak sales potential of $250 million to $350 million annually[74] Keveyis (dichlorphenamide) for Primary Periodic Paralysis - Keveyis generated an expected revenue of $28 million to $29 million in 2020[6] - The total addressable market for Keveyis is more than $500 million annually[6] - Strongbridge believes Keveyis has the potential to exceed peak sales of $50 million annually[126] Financial Position - Strongbridge projects it can fund operations into and potentially beyond Q1 2023, with approximately $82 million in cash as of September 30, 2020[131, 132]